Cure8 research brief
The study identifies a probiotic species (B. pseudolongum) and its acetate production as potential ways to limit a genotoxic E. coli and reduce inflammation in a mouse model — suggesting a microbiome-based avenue that could eventually inform new treatments for ulcerative colitis if validated in humans.
Researchers (microbiome, microbiology, IBD therapeutics), clinicians following microbiome interventions, and adult patients interested in emerging probiotic research
The paper reports experiments in mice, not people. In mice colonized with a pks+ E. coli strain, administering putrescine shifted the gut microbiota and increased B. pseudolongum abundance. Giving B.
pseudolongum or increasing acetate levels was associated with lower colitis severity, higher colonic acetate, activation of PPAR-γ, and competitive inhibition of the E. coli strain in functional assays.
The findings point to a possible probiotic or metabolite-driven strategy to control harmful gut bacteria and inflammation, but these are preclinical results that require further testing in human studies before any clinical recommendations.
Preclinical mouse model (DSS-induced colitis with colonization by a pks+ E. coli strain). Results are promising but preliminary; human studies are needed to determine safety, appropriate strains/doses, and clinical benefit.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study identifies a fungal β-glucan that reduced inflammation and altered the gut microbiome and short-chain fatty acids in a mouse model of ulcerative colitis, which could inform future nutritional or therapeutic...
People with ulcerative colitis may be interested because synbiotic approaches aim to change the gut microbiome and intestinal barrier and therefore could become a future therapeutic option or adjunct. The paper...
The study identifies a plant-derived compound that reduced inflammation and liver injury in a mouse model of ulcerative colitis and ties its effects to both JAK2/STAT1 inhibition and changes in the gut microbiota—two...
